The Story of Lenalidomide: A Major Advance in Treatment
SHARE

Fact Checked

SurvivorNet Fact Checking and Medical Review Standards:  

The SurvivorNet News Team creates high quality medical information that complies with our industry leading standards for factual accuracy and sourcing from leading experts at academic medical institutions. Every news article is thoroughly fact-checked by our physician collaborators. We vet each piece of work for factual integrity, impartiality, and clearly label any professional conflicts.

All SurvivorNet articles adhere to the following standards:

  1. All studies and research papers cited are from reputable academic medical institutions or peer-reviewed journals.
  2. When we use data, statistics, or quotes these references link to the original source.
  3. All content related to new treatments, drugs, procedures, and so on must clearly describe availability, side effects, treatment target (such as triple negative breast cancer)
  4. All medical information on SurvivorNet is sourced from respected medical professionals with verified medical credentials and links are provided to these sources.
  5. We strive to give the reader relevant background information and include, clearly-sourced contextual health information in all articles. Readers are clearly alerted to any conflicts of interest from a medical source or the authors of a cited study.
/ Updated December 11th, 2024

The Story of Lenalidomide: A Major Advance in Treatment

Medical Source: Dr. Vincent Rajkumar
Mayo Clinic
×

Lenalidomide, also known as its trade name Revlimid, is currently a mainstay in multiple myeloma treatment. In newly diagnosed patients, standard doses of lenalidomide, in combination with other therapies, is used to kill myeloma cells. Later on in treatment, low doses of lenalidomide is used to keep the immune system on high alert in case the cancer begins to come back following chemotherapy.

However, thalidomide, the precursor to lenalidomide, was initially not developed as a treatment for multiple myeloma. “The story of thalidomide is one of the most fascinating stories in all of medicine,” remembers Dr. Vincent Rajkumar, medical oncologist at the Mayo Clinic and one of the key players in getting lenalidomide federally approved for multiple myeloma treatment.  “Thalidomide was developed as a sleeping pill in the late 50s. And when it was developed nobody knew its precise mechanism of action. They just knew that if you took it, you felt sleepy.”

Read More
The drug rose to prominence because patients could not overdose from it, an anomaly amongst sleeping pills at the time. It wasn’t until the early 60s when pregnant women who had taken thalidomide to help deal with morning sickness gave birth to babies with malformations. But in the 70s the drug was suspected to have other mechanisms.

In 1971 the concept of anti-angiogenesis was discovered which involves blocking the formation of new blood vessels necessary for a tumor to grow and survive.”Thalidomide was thought to be an anti-angiogenic drug. That is, it prevented the growth of new blood vessels.” That’s when thalidomide, and then lenalidomide, came to the forefront again. “The theory was that cancers can grow only until one millimeter in size, unless they are able to induce new blood vessels. And if they are not able to induce new blood vessel formation, the cancer will shrink and die,” Rajkumar explains. Lenalidomide gained approval for widespread use in multiple myeloma in the late-2000’s.

“I think finally now we understand how these drugs probably work.” says Rajkumar. Research has determined that Lenalidomide accelerates the breakdown of proteins in cancer cells critical to tumor growth and survival. By doing so, lenalidomide can increase the survival of patients with multiple myeloma by several years–a noble next chapter for a drug with fascinating beginnings.

Learn more about SurvivorNet's rigorous medical review process.

Dr. S. Vincent Rajkumar, MD is engaged in clinical, epidemiological and laboratory research in myeloma and related disorders. Read More

close

Patient Pathfinder

We’re here to help. Have you had any treatment for myeloma yet?

You might want to check out some top experts outlining the initial treatment for myeloma.

Here’s the link:


Multiple Myeloma Initial Treatment

Learn More

Got it. Are you looking for maintenance treatment?

You might want to check out some top experts outlining maintenance treatment for myeloma.

Here’s the link:


Multiple Myeloma Maintenance Treatment

Learn More

Ok. Has your Myeloma come back? Here are some useful resources:

Here’s the link:


Multiple Myeloma Reoccurrence Treatment

Learn More

If you’ve had at least four treatments that have not worked or stopped working you might be a candidate for a treatment called CAR T Therapy.

Here’s the link:


CAR-T Therapy for Multiple Myeloma

Learn More
First Treatment for Multiple Myeloma

Many people will begin their treatment for multiple myeloma with a combination of three drugs called induction therapy.

NOW
PLAYING
First Phase Treatment - How Will I Feel?
NOW
PLAYING
Myeloma Initial Treatment: How Will I Feel?
NOW
PLAYING
Early-Stage Treatment Standard of Care Triplet Therapy
NOW
PLAYING
Treatment for Multiple Myeloma Induction Therapy
NOW
PLAYING
Standard Risk vs. High Risk Multiple Myeloma
NOW
PLAYING
Initial Treatment: Should You Receive Monoclonal Antibodies?

My Health Questions

Powered by SurvivorNet

Rapid evidence support for real-world oncology decisions.

Not sure where to start? Try these prompts.

icon

Can you help me find clinical trials for Multiple Myeloma?

icon

What is lenalidomide and how does it work in treating multiple myeloma?

icon

What are the side effects of lenalidomide compared to traditional chemotherapy?

icon

How did thalidomideu2019s history influence the development of lenalidomide?

Continue The Journey

Explore: Maintenance Treatment

Related Articles

62-Year-Old Dad’s Agonizing Back Pain & Numb Feet Turned Out To Be Multiple Myeloma

In Their ‘Glory Days,’ Singer-Songwriter Bruce Springsteen & His Beloved Wife Patti Scialfa, Who Is Living With Multiple Myeloma, Celebrate 34 Years Married

Overview

New NBC Nightly News Anchor, 46, Honors Tom Brokaw, 85 — A Journalist & Remarkable Cancer Survivor

61-Year-Old Dad of Two’s Loss Of Appetite, Fatigue, Back Pain, & Unexplained Weight Loss Turned Out To Be Rare Blood Cancer— Understanding Multiple Myeloma

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider